AstraZeneca is beginning Phase 3 trial of Oxford COVID-19 vaccine in U.S.


AstraZeneca began a Phase 3 U.S. human trial of its COVID-19 vaccine on Tuesday, hoping to enroll up to 30,000 people to test its shot, developed with Britain's Oxford University. This will be the third final-stage trial of a COVID-19 vaccine in the U.S., joining efforts by Moderna and Pfizer. The U.K. is already in the midst of its AstraZeneca-Oxford Phase 3 trial, and preliminary results could be released as early as October.
The U.S. trial's launch had been postponed for a couple of days for reasons researchers could not explain, Bloomberg reports. But William Hartman, a University of Wisconsin investigator helping to lead the trial, and AstraZeneca CEO Pascal Soriot both emphasized that the research will be conducted carefully, rigorously, and free of political pressure. An article Thursday in the Palm Beach Post had speculated that U.S. regulators were pressured into delaying the trial so as to pave the way for emergency use authorization before the U.S. presidential election.
A poll from Stat News-Harris released Monday found that 78 percent of Americans worry that the COVID-19 approval process is being guided more by politics than science. At the same time, 68 percent said they don't think the FDA will approve a vaccine unless they are convinced it is safe.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
‘A legacy news brand brings a visibility of its own’
Instant Opinion Opinion, comment and editorials of the day
-
8 of the best ‘cozy crime’ series of all time
The Week Recommends Murder mysteries don’t necessarily have to make us miserable, and these shows have perfected a feel-good crime formula
-
Youth revolts rattle Morocco as calls against corruption grow louder
THE EXPLAINER Snowballing controversy over World Cup construction and civic services has become a serious threat to Morocco’s political stability
-
Gold tops $4K per ounce, signaling financial unease
Speed Read Investors are worried about President Donald Trump’s trade war
-
Electronic Arts to go private in record $55B deal
speed read The video game giant is behind ‘The Sims’ and ‘Madden NFL’
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance